azeliragon

orally bioavailable small molecule inhibitor of RAGE (Receptor for Advanced Glycation Endproducts)

Also Known As:

1-Propanamine, 3-(4-(2-butyl-1-(4-(4-chlorophenoxy)phenyl)-1H-imidazol-4-yl)phenoxy)-N,N-diethyl-; 3-(4-(2-Butyl-1-(4-(4-chlorophenoxy)phenyl)-1H-imidazol-4-yl)phenoxy)-N,N-diethyl-1-propanamine; TTP488

Networked: 10 relevant articles (4 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - azeliragon: 10

Experts

1.	Burstein, Aaron H: 2 articles (01/2019 - 01/2014)
2.	Jia, Peng: 1 article (06/2021)
3.	Xue, Jie: 1 article (06/2021)
4.	Yao, Zhiwen: 1 article (06/2021)
5.	Zhang, Dong: 1 article (06/2021)
6.	Chen, Xin: 1 article (04/2021)
7.	Huang, Bo: 1 article (04/2021)
8.	Li, Jiahui: 1 article (04/2021)
9.	Li, Rui: 1 article (04/2021)
10.	Tang, Haixiong: 1 article (04/2021)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/2019 - "To address this question, we treated young (4-mo) and middle-aged (15-mo) C57BL/6 female mice with vehicle or Azeliragon, a small-molecule RAGE inhibitor initially developed to treat Alzheimer's disease. " 01/15/2014 - "Effect of TTP488 in patients with mild to moderate Alzheimer's disease." 06/01/2021 - "TTP488 ameliorates NLRP3-associated inflammation, viability, apoptosis, and ROS production in an Alzheimer's disease cell model by mediating the JAK1/STAT3/NFκB/IRF3 pathway." 01/01/2021 - "Azeliragon ameliorates Alzheimer's disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway." 06/01/2021 - "SIGNIFICANCE OF THE STUDY: This study explores the role of TTP488 in the development of an Alzheimer's disease (AD) cell model and confirms that TTP488 administration notably promotes cell proliferation and reduces apoptosis, inflammatory factor expression, and reactive oxygen species generation. "
2.	Inflammation (Inflammations) 06/01/2021 - "Moreover, we found that WP1160 counteracted the role of TTP488 in Aβ-induced SH-SY5Y cells' viability, inflammation, apoptosis, and ROS production. " 06/01/2021 - "TTP488 ameliorates NLRP3-associated inflammation, viability, apoptosis, and ROS production in an Alzheimer's disease cell model by mediating the JAK1/STAT3/NFκB/IRF3 pathway." 04/01/2021 - "Treatment of FPS-ZM1 or Azeliragon not only effectively descended the expression of RAGE and its ligands but also attenuated LPS-induced neutrophil-predominant airway inflammation and injury, decreased levels of IL-6, IL-1β and TNF-α in BALF, alleviated increased alveolar-capillary permeability and pulmonary edema. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 06/05/2023 - "Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer." 06/05/2023 - "Collectively, our findings revealed previously unreported aspects of the drug azeliragon, and identified a novel combination strategy for the treatment of pancreatic cancer patients." 06/05/2023 - "Cell experiments revealed that azeliragon abolished PAK1 activation and promoted apoptosis in pancreatic cancer cells. " 06/05/2023 - "Azeliragon was also found to significantly inhibit tumor growth in a pancreatic cancer xenograft model; when combined with afuresertib, an oral pan-AKT kinase inhibitor, azeliragon exhibited a strong synergistic effect against pancreatic cancer cells. "
4.	Diabetic Neuropathies (Diabetic Neuropathy) 01/01/2023 - "Blockade of receptor for advanced glycation end-products with azeliragon ameliorates streptozotocin-induced diabetic neuropathy."
5.	Cognitive Dysfunction 01/01/2018 - "The ongoing Phase 3 program, if successful may demonstrate azeliragon can slow cognitive decline in mild AD patients." 01/01/2018 - "Preclinical studies in animal models of AD (tgAPPSwedish/London) have shown azeliragon to decrease Aβ plaque deposition; reduce total Aβ brain concentration while increasing plasma Aβ levels; decreases sAPPβ while increasing sAPPα; reduce levels of inflammatory cytokines; and slow cognitive decline and improve cerebral blood flow. "

Related Drugs and Biologics

1.	Receptor for Advanced Glycation End Products
2.	Streptozocin (Streptozotocin)
3.	Protein-Tyrosine Kinases (Tyrosine Kinase)
4.	Reactive Oxygen Species (Oxygen Radicals)
5.	Cytokines
6.	azeliragon
7.	FPS-ZM1
8.	Interleukin-6 (Interleukin 6)
9.	Proteins (Proteins, Gene)
10.	Phosphotransferases (Kinase)